Cinromide plus ASMs vs placebo plus ASMs
Number of participants with ≥ 75% reduction in mean weekly seizures · Lennox‐Gastaut syndrome, any age
It is very uncertain whether cinromide plus ASMs changes number of participants with ≥ 75% reduction in mean weekly seizures compared with placebo plus ASMs (very low certainty).
1 finding from 1 review
- Peto OR 9.35 [0.45, 194.96]1 study · 56 participantsVery low